Table 1.
Characteristics of included studies.
| Author, Year | Name of the Vaccine | Study design | Controlled/vaccinated subjects | Age (year), Male% | Local reactions | Systemic reactions |
|---|---|---|---|---|---|---|
| Xia, 2020 [30] | BBIBP-CorV | Randomized double-blind placebo-controlled phase I/II trials | 80/240 | Mean age: 42.8 Male: 37.5% | Pain itching redness swelling | Fever, coughing diarrhea, fatigue headache, pruritus nausea, vomiting |
| Xia, 2020 [31] | CoronaVac-Wuhan | Randomized double-blind placebo-controlled studies phase I/II trial | 160/480 | Mean age: 45.3 Male: 45.7% | Pain itch redness swelling rash | Fever, fatigue inappetence, nausea, diarrhea, joint pain, Headache, Vomiting |
| Xia, 2020 [29] | BBIBP-CorV | Randomized double-blind placebo-controlled studies phase I/II trial | 160/480 | Age range: 3–18 Male: 51% | Pain itch redness swelling rash | Fever, fatigue inappetence, nausea, diarrhea, joint pain, Headache, Vomiting |
| Zhang, 2020 [32] | CoronaVac | Double-blind randomized placebo-controlled phase I/II clinical trial | 167/576 | Mean age:42.4 Male: 44.6% | Pain swelling redness discoloration | Fatigue, diarrhea fever, muscle pain, headache, nausea, cough, hypersensitivity |
| Wu, 2021 [28] | CoronaVac | Double-blind randomized placebo-controlled phase I/II clinical trial | 73/498 | Mean age: 66.5 Male: 48.9% | Pain swelling erythema pruritus | Fatigue, diarrhea fever, muscle pain headache, nausea cough, hypersensitivity |
| Che, 2020 [19] | Double-blind randomized placebo-controlled phase II clinical trial | 150/600 | Mean age: 39.2Male: 37.7% | Pain Redness Swelling Itch | Fever, Fatigue Diarrhea, Hypersensitivity/urticaria, Cough, Nausea Vomiting Mucosal abnormality | |
| Kremsner, 2021 [22] | CVnCoV | Randomized, double-blind, placebo-controlled phase I | 30/120 | Mean age: 45.8 Male: 42.8% | Pain redness swelling | Headache, fatigue myalgia,,nausea/vomiting, diarrhea |
| Zhu, 2020 [33] | Ad5-vectored | Randomized double-blind placebo-controlled phase II trial | 126/382 | Mean age: 39.7 Male: 50.0% | Pain swelling redness induration itch | Fever, headache, fatigue, vomiting, diarrhea, muscle pain, joint muscle, cough, nausea |
| Folegatti, 2020 [20] | ChAdOx1 | Participant-blinded; multicenter randomized controlled trial phase I/II | 534/543 | Median age: 35 Male: 50.2% | Pain swelling redness itch induration tenderness | Chills, fatigue, fever, feverish, headache, joint pain, malaise, nausea, muscle ache |
| Ramasamy, 2020 [25] | ChAdOx1 | single-blind, randomized, controlled, phase II/III trial | 140/420 | Median age, 18–55 years group: 43.0 56–69 years group: 60.0 70 years and older: 73.0 Male,50.0% | Pain, swelling redness itch induration tenderness | chills, fatigue, fever, feverish, headache, joint pain, malaise, nausea, muscle ache |
| Baden, 2020 [18] | mRNA-1273 | phase III randomized observer-blinded placebo-controlled trial | 15179/15181 | Mean age: 52.4 Male: 52.7% | Pain, Erythema, Swelling, Lymphadenopathy | Fever, Headache, Fatigue, Myalgia, Arthralgia, Chills Nausea, Vomiting |
| Walsh, 2020 [27] | BNT162b1 | placebo-controlled, observer-blinded, randomized dose-escalation,phase I trial | 21/84 | Median age (BNT162b1): younger group:35 group: 69 BNT162b2: younger group: 37 older group: 68 Male: 44.8% | pain redness swelling | fever fatigue chills |
| Mulligan, 2020 [23] | BNT162b1 | placebo-controlled, observer-blinded, randomized, Phase I/II trial | 9/36 | Mean age: 35.4 Male: 51.1% | pain redness swelling | fever, fatigue, chills, headache, vomiting, diarrhea, muscle pain, joint pain |
| Polack, 2020 [24] | BNT162b2 | placebo-controlled, observer-blinded, randomized, Phase III trial | 18846/18860 | Median age: 52 Male: 50.6% | pain redness swelling | fever, fatigue, chills, headache, vomiting, diarrhea, muscle pain, joint pain |
| Richmond, 2020 [26] | SCB-2019 | placebo-controlled, blinded, phase I trial | 32/216 | Mean age: 38.6 Male: 57% | pain redness swelling itching | fever, fatigue, chills, headache, vomiting, diarrhea, myalgia |
| Keech, 2020 [21] | NVX-CoV2373 | randomized, placebo-controlled, phase 1/2 trial | 23/108 | Mean age: 29.5 Male: 40% | pain redness swelling itching | fever, fatigue, chills, headache, vomiting, diarrhea, myalgia |
| Khobragade, 2022 [34] | ZyCoV-D | randomized, placebo-controlled, phase III trial (first dose) | 487/447 | younger population: 12–17 years | pain redness swelling itching | fever, fatigue, headache |
| Khobragade, 2022 [34] | ZyCoV-D | randomized, placebo-controlled, phase III trial (first dose) | 923/924 | older population: greater than60 years | pain swelling | myalgia, headache, fatigue, fever, |
| Masuda, 2022 [35] | NVX-CoV2373 | randomized, placebo-controlled, phase 1/2 trial | 50/150 | Mean age: 52.6 | pain redness swelling itching induration | fever, fatigue, chills, headache, vomiting, diarrhea, myalgia |
| Tabarsi, 2022 [36] | SpikoGen | randomized, placebo-controlled, phase 2 trial | 89/311 | Mean age: 35.69 | pain redness swelling itching induration | fever, fatigue, chills, headache, vomiting, diarrhea, myalgia |